

Central Lancashire Online Knowledge (CLoK)

Title	Effect of zinc intake on serum/plasma zinc status in infants: A meta-analysis
Туре	Article
URL	https://clok.uclan.ac.uk/6857/
DOI	https://doi.org/10.1111/mcn.12045
Date	2013
Citation	Nissensohn, M, Sánchez Villegas, A, Fuentes Lugo, D, Henríquez Sánchez, P, Doreste Alonso, J, Lowe, Nicola M, Moran, Victoria Louise, Skinner, Anna- louise, Warthon-medina, Marisol et al (2013) Effect of zinc intake on serum/plasma zinc status in infants: A meta-analysis. Maternal And Child Nutrition, 9 (3). pp. 285-298. ISSN 1740-8695
Creators	Nissensohn, M, Sánchez Villegas, A, Fuentes Lugo, D, Henríquez Sánchez, P, Doreste Alonso, J, Lowe, Nicola M, Moran, Victoria Louise, Skinner, Anna- louise, Warthon-medina, Marisol and Serra-Majem, L

It is advisable to refer to the publisher's version if you intend to cite from the work. https://doi.org/10.1111/mcn.12045

For information about Research at UCLan please go to http://www.uclan.ac.uk/research/

All outputs in CLoK are protected by Intellectual Property Rights law, including Copyright law. Copyright, IPR and Moral Rights for the works on this site are retained by the individual authors and/or other copyright owners. Terms and conditions for use of this material are defined in the <u>http://clok.uclan.ac.uk/policies/</u>



Effect of zinc intake on serum/plasma zinc status in infants: A meta-analysis.

Journal:	Maternal & Child Nutrition
Manuscript ID:	MCN-08-12-RA-0777.R2
Manuscript Type:	Review Article
Keywords:	Epidemiology, Infant and Child Nutrition, Micronutrients, Nutritional Status, Systematic Review, Zinc



1	Effect of zinc intake on serum/plasma zinc status in infants: A meta-analysis.
2	
3	Nissensohn M ^{1'2*} , Sánchez Villegas A ^{1'2} , Fuentes Lugo D ³ , Henríquez Sánchez P ^{1'2} , Doreste
4	Alonso J ¹ , Lowe NL ⁴ , Hall Moran V ⁵ , Skinner AL ⁴ , Warthon Medina M ⁴ , Serra-Majem L ^{1'2}
5	
6	¹ Department of Clinical Sciences, University of Las Palmas de Gran Canaria, P.O. Box 550,
7	35080 Las Palmas de Gran Canaria, Spain (MN mnissensohn@acciones.ulpgc.es; ASV
8	asanchez@dcc.ulpgc.es; PHS phenriquez@dcc.ulpgc.es; JDA jdoreste@dcc.ulpgc.es; LSM
9	lserra@dcc.ulpgc.es)
10	² Ciber Fisiopatología Obesidad y Nutrición (CIBEROBN, CB06/03), Instituto de Salud Carlos III, Spain (MN
11	mnissensohn@acciones.ulpgc.es; ASV asanchez@dcc.ulpgc.es; PHS phenriquez@dcc.ulpgc.es;
12	LSM <u>lserra@dcc.ulpgc.es</u>)
13	³ Faculty of Health Sciences, Unacar, Ciudad del Carmen, Mexico (DFL daniel.fuentes@mac.com)
	⁴ International Institute of Nutritional Sciences and Food Safety Studies, University of Central
	Lancashire, Preston PR1 2HE, UK (NL NMLowe@uclan.ac.uk; ALS ASkinner@uclan.ac.uk;
	MWM <u>MWathonmedina1@uclan.ac.uk</u>)
14	⁵ Maternal & Infant Nutrition & Nurture Unit, University of Central Lancashire, Preston PR1 2HE,

- 15 UK. (VHM <u>vlmoran@uclan.ac.uk</u>)
- 16 *Corresponding Author:
- 17 Nissensohn Mariela, Department of Clinical Sciences, University of Las Palmas de Gran Canaria,
- 18 Las Palmas de Gran Canaria, Spain
- 19 phone: 0034 928 459816

20 fax: 0034 928 451416

- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- *___*
- 30

31 Abstract

A systematic review and meta-analysis of available RCTs was conducted to evaluate the effect of zinc (Zn) intake on serum/plasma Zn status in infants. Out of 5500 studies identified through electronic searches and reference lists, 13 RCTs were selected after applying the exclusion/inclusion criteria. The influence of Zn intake on serum/plasma Zn concentration was considered in the overall meta-analysis. Other variables were also taken into account as possible effect modifiers: doses of Zn intake, intervention duration, nutritional status and risk of bias. RESULTS: The pooled β of status was 0.09 (CI 0.05 to 0.12). However, a substantial heterogeneity was present in the analyses ($I^2 = 98\%$; p=0.00001). When we performed a meta-regression, the effect of Zn intake on serum/plasma Zn status changed depending on the duration of the intervention, the dose of supplementation and the nutritional situation (p ANCOVA= 0.054; <0.001 and <0.007 respectively). After stratifying the sample according to the effect modifiers the results by duration of intervention showed a positive effect when Zn intake was provided during medium and long periods of time (4-20 weeks and \geq 20 weeks). A positive effect was also seen when doses ranged from 8.1 to 12 mg/day. In all cases, the pooled β showed high evidence of heterogeneity. CONCLUSION: Zn supplementation increases serum/plasma Zn status in infants, although high evidence of heterogeneity was found. Further standardized research is urgently needed to reach evidence-based conclusions to clarify the role of Zn supplementation upon infant serum/plasma Zn status, particularly in Europe. Keywords: EURRECA, zinc intake, serum/plasma Zn status, infants

66 Introduction

67

Zinc (Zn) is an essential nutrient, present in all body tissues and fluids. The biologic role of Zn is now recognized in the structure and function of proteins, including more than 300 enzymes, transcription factors, hormonal receptor sites, and biologic membranes. Zn has numerous central roles in DNA and RNA metabolism (MacDonald 2000), and it is involved in signal transduction, gene expression, and apoptosis. Zn enzymes are involved in nucleic acid metabolism and cellular proliferation, differentiation, and growth (Chesters 1978).

Plasma Zn accounts for only about 0.1 per cent of the total body content. Zn has a rapid turnover, and its level appears to be under close homeostatic control. There is no 'store' for Zn in the conventional sense (Milne et al. 1983) and it is present in the body almost exclusively as Zn2+ bound to cellular proteins (Makonnen et al. 2003).

78 Assessment of the Zn nutriture of individuals is complicated by the fact that no generally accepted. 79 sensitive and specific biomarker of serum/plasma Zn status exists (King 1990). Although it is true 80 that serum/plasma Zn concentrations decrease within several weeks of the introduction of a diet 81 containing a severely restricted amount of Zn (Baer et al. 1985), serum/plasma Zn concentrations 82 are generally maintained within the normal range with small or moderate reductions in Zn intake. 83 Moreover, factors unrelated to the level of Zn nutriture, such as recent meals, time of day, infection, 84 tissue catabolism, and pregnancy, can also affect serum/plasma Zn concentrations (King 1990; 85 Hambidge & Krebs 1995). Thus, the serum/plasma Zn concentration may not always be a reliable 86 indicator of an individual's true Zn status (Brown et al. 2002). Nevertheless a recent systematic 87 review concluded that serum/plasma Zn concentration was responsive to both Zn supplementation 88 and depletion and it remains the most widely used biomarker for Zn (Lowe et al. 2009).

89

90 Infants have a relatively high requirement of Zn per unit body weight during a sensitive period of 91 rapid growth and development (Hermoso et al. 2010). Recommendations for Zn intake during 92 infancy vary widely across Europe, ranging from 1 mg/day up to 5 mg/day (Hermoso et al. 2010). 93 The EURRECA project attempts to consolidate the basis for the definition of micronutrient 94 requirements across Europe, taking into account relationships among intake, status and health 95 outcomes, in order to harmonise these recommendations (Ashwell et al. 2008). This paper presents 96 a systematic review of the data from all available randomized controlled trials (RCTs) meeting 97 EURRECA's quality standard (Matthys et al. 2011), which investigated Zn intake and biomarkers

98 of Zn status in infants, and combines these studies in meta-analyses to model Zn concentrations in

- 99 serum or plasma as a function of Zn intake.
- 100
- 101 Materials and Methods

102 Search strategy

103

104 This research was conducted within the framework of the European Micronutrient 105 Recommendations Aligned (EURRECA) Network of Excellence that aims to identify the 106 micronutrient requirements for optimal health in European populations (www.eurreca.org). This 107 review was part of a wider review process to identify studies assessing the effect of Zn intake on 108 different outcomes (biomarkers of Zn status and health outcomes). The wider searches were 109 performed of literature published up to and including February 2010, and an updated search was 110 carried out in January 2013. The databases MEDLINE, EMBASE and Cochrane using search terms 111 for "study designs in humans" and "zinc" and "intake". Both indexing and text terms were used and 112 languages included were restricted to those spoken in the EURRECA Network (English, Dutch, 113 French, German, Hungarian, Italian, Norwegian, Polish, Spanish, Greek, and Serbian.). The Ovid 114 MEDLINE search strategy can be found in Table 1. Reference lists of retrieved articles and 115 published literature reviews were also checked for relevant studies. The procedure for the 116 identification, selection of articles and data extraction is illustrated in Figure 1.

117 Selection of articles

Titles of articles identified from the searches were entered into an EndNote library. Papers were considered eligible for inclusion if they were RCTs, conducted in human infants (aged 0-12 months), and studied the effect of supplements, fortified foods or micronutrient intake from natural food sources, and assessed Zn concentrations in serum / plasma. Zn intake was assessed from breast milk, infant formula and food sources (e.g. complementary foods), fortified foods (e.g. fortified formula or cereal) and supplements.

Exclusion criteria applied were: studies conducted in animals; combined interventions e.g. >1 micronutrient or micronutrient + lifestyle intervention which did not study the effect of the micronutrient separately; non primary studies (e.g. letters & narrative literature reviews); duplicate publications; studies where the Zn intake – status relationship was not reported or biomarkers of Zn other than serum / plasma Zn were used.

129 Briefly, titles and abstracts of the 10% of the library were screened in duplicate for eligibility by 130 two reviewers and any discrepancies were discussed and resolved before screening the remaining 131 references. Only when both reviewers agreed that titles and abstracts met the inclusion criteria were 132 the articles included. When a title and abstract could not be included with certainty, the full text of 133 the article was obtained and then further evaluated. The remaining 90% was distributed among the 134 two reviewers in even parts. Following the initial screening process, full-text articles were obtained. 135 Further inclusion and exclusion criteria were then applied. Papers were only included in the meta-136 analysis if they were: randomised controlled trials; had an intervention duration of at least 2 weeks; 137 and reported baseline data for all outcome measures. Non-randomised controlled trials, uncontrolled 138 trials or trials reporting insufficient or unclear data were excluded. Data were extracted from each 139 study and organized in a Microsoft Access database file (Microsoft Corp, Redmond, WA).

140

141 **Data synthesis**

142 When Zn status in serum/plasma was measured at different time points within the same population, 143 we used the measures as different estimations (Bates et al. 1993; Makonnen et al. 2003 I/II). One 144 study reported data from the total of infants included, between males and females separately, and 145 according to age (<11 months and > 11 months) (Sazawal et al. 1996; 2004) and it was treated as 146 five estimations within the meta-analysis. One study reported data from two groups of infants 147 (stunted and non stunted) and these were treated as two different estimations (Umeta et al. 2000). 148 One study reported data from two groups according to the form of Zn supplementation (tablets or 149 liquid) and these were treated as two estimations within the meta analysis (Wessells et al. 2012). Of 150 the selected studies, two RCTs were companion papers (Makonnen et al. 2003 I; Sazawal et al. 151 2004). If dietary intake of Zn (in addition to the intervention) was not reported in the RCTs, we 152 imputed a value of 1.3 mg/day, the mean dietary intake level of the RCTs that did report dietary Zn 153 intake. As mean baseline serum/plasma Zn concentrations were infrequently reported in the RCTs, 154 most of the RCTs assumed no differences in baseline serum/plasma Zn concentrations (n= 12). 155 Only one study, Bates et al. 1993, failed to report anything regarding baseline serum /plasma Zn 156 concentrations.

157

- 158 *Exposure and outcome and other covariates assessment:*
- 159

160 The influence of Zn intake on serum/plasma Zn concentrations was considered in the overall meta-

161 analysis. Other variables were also taken into account as possible effect modifiers. We considered

doses of Zn intake (1 to 4 mg, 4.1 to 8 mg, 8.1 to 12 mg, and >12.1 mg), intervention duration (1 to

163 3 weeks, 4 to 20 weeks, and > 20 weeks), nutritional situation (healthy, nutritionally at risk, and

164 poor nutritional status) and risk of bias (low, moderate or high).

165

166 Assessment of nutritional situation in included studies

167

Nutritionally at risk was defined as infants who lived in low income families with a low socioeconomic situation and poor nutritional status was defined as infants with protein energy malnutrition (PEM) but without congenital abnormalities or cerebral palsy or heart disease or infants with low birth weight during their first year. PEM occurs characteristically in children under years of age in circumstances where the diet is poor in protein, calories and micronutrients, and insufficient to satisfy the body's nutritional needs. It remains one of the most common causes of morbidity and mortality among children worldwide (WHO, 1999).

175

176 Assessment of risk of bias in included studies

177 Risk of bias was assessed in order to evaluate the quality of the studies included. The following 178 indicators of internal validity specific to the RCT methodology were collected during data 179 extraction: 1) method of sequence generation and 2) adequate allocation, 3) blinding, 4) number of 180 participants at start, dropouts and dropout reasons, 5) outcome data complete, 6) funder adequate 7) 181 other potential funding bias . Based on these indicators, two reviewers assessed the overall risk of 182 bias. Disagreements were resolved by discussion. The criteria for judging these indicators were 183 adapted from the Cochrane Handbook for Systematic Reviews (Higgins & Green 2009) (Table 2).

184

185 Statistical analyses

186

187 Mean and standard deviation (SD) or standard errors (SE) of the outcome (serum/plasma Zn) were 188 assessed. From the mean and SD of each study beta values (β) and their SE were calculated because 189 the statistical model that we used to estimate the relation between Zn intake (x-variable) and 190 serum/plasma Zn (y- variable) is based on the assumption that this intake-serum/plasma Zn status 191 curve is a logarithmic function and that both intake and serum/plasma Zn status follow a log-normal 192 distribution (the natural logarithm of intake and serum/plasma Zn status have a normal distribution). 193 Thus, the expected value of the serum/plasma Zn status score is expressed as: 194 $\mu y = \beta * \mu x + \text{intercept}$, where μy represents the mean of the natural logarithm of the y-variable (=

195 serum/plasma Zn status score), β represents the regression coefficient, and μx represents the mean

196 of the natural logarithm of the x-variable (= Zn intake). The method used to systematically review

- 197 differences was a formal meta-analysis (Greenland 1998). A random-effects model was considered
- 198 to be more appropriate than a fixed-effects model. We used the DerSimonian and Laird's
- 199 (DerSimonian & Laird 1986) to pool the estimates of betas across studies. Under this model, the
- 200 pooled effect was the beta in the status parameter (serum / plasma), for an increment of 1 unit in Zn
- 201 intake. A pooled beta estimate was calculated as a weighted average of the beta reported in each
- study.
- 203 The formula we used to estimate the weighted effect size was (Hedges 1982):
- 204 $\beta pooled = \sum \beta i wi / \sum wi$
- 205 where β pooled is the pooled estimate of the beta in status parameters; the weight *(wi)* of each study

206 was computed as:

 $207 \quad wi = 1 / Vi + z^2$

- 208 where *V* is the variance of each study and τ^2 is the inter study variance.
- 209 Besides this, we calculated a 95% confidence interval for the pooled estimated of effect size:
- 210 95% CI= β pooled ± (1.96 x SE pooled)
- 211 where SE is the standard error of the pooled estimate (Greenland 1998).
- 212

213 A test of heterogeneity was calculated, estimating Q statistics, which follows a chi-square 214 distribution with degrees of freedom n-1, n being the number of studies included in the analysis. 215 The I² Index measures the extent of the heterogeneity. A low P value for this statistic (lower than 216 (0.05) indicates the presence of heterogeneity, which somewhat compromises the validity of the 217 pooled estimates (Takkouche et al. 1999). Because significant heterogeneity was clearly evident in 218 the pooled beta estimates for all studies combined in each outcome, we evaluated potential sources 219 of heterogeneity by linear meta-regressions (Greenland 1998). We fitted a meta-regression using the 220 duration of the intervention, the doses of Zn intake, the risk of bias, and the nutritional situation as 221 independent variables. The betas of the different status parameters according to Zn intake were used 222 as the dependent variable. Statistical differences in multivariate adjusted mean beta values between 223 each possible heterogeneity sources were determined by ANCOVA. Additionally we carried out 224 additional meta-analyses by subgroups considering only those groups which provided significant 225 values in the meta-regression. Microsoft Excel Version (7.0), SPSS 10.0 for Windows and Review 226 Manager 5.1, were used to conduct the statistical analyses.

227

228 Results

- 229
- Five thousand five hundred articles were identified in the initial search strategy. After applying the exclusion / inclusion criteria, 344 articles from the search appeared to be potentially relevant. After
 - 7

applying the additional eligibility criteria and grouping the studies by outcome, 9 randomized
controlled trials (17 estimations) were selected (Walravens et al. 1989; Bates et al. 1993; Sazawal et
al. 1996, 2004; Umeta et al. 2000; Osendarp et al. 2002; Lind et al. 2003; Makonnen et al. 2003;

235 Wasantwisut et al. 2006; Chang et al 2010). The 2013 update of the original search identified 4

additional articles (Berger et al. 2006; Mazariegos et al. 2010; Ba Lo et al. 2011; Wessells et al.

237 2012), providing a total of 13 articles (22 estimates) for meta-analysis (Figure 1).

238

239 Descriptive characteristics of the studies included in the meta-analysis are presented in Table 2. Of 240 the 13 studies included, only six comply strictly with the age infants (0 to 12 months) (Umeta et al. 241 2000; Osendarp et al. 2002; Lind et al. 2003; Berger et al. 2006; Wasantwisut et al. 2006; 242 Mazariegos et al. 2010). The other seven studies included this age among their sample, but did not 243 clarify how many are actually aged 0 to 12 months (Walravens et al. 1989; Bates et al. 1993; 244 Sazawal et al. 1996, 2004; Makonnen et al. 2003; Chang et al 2010; Ba Lo et al. 2011; Wessells et 245 al. 2012). None of the ages extended beyond 27 months, except Makonnen et al. 2003 which 246 included children up to 5 years. Thus the age range of the studies included was from 3 weeks to 60 247 months.

248

249 Six studies were conducted in Asia, one in North America, one in Latin America and the Caribbean

and five in Africa. The duration of the interventions ranged from 2 to 24 weeks. Doses of Zn intake

ranged from 2.5 to 20 mg per day. The nutritional situation of infants also varied between studies:

six studies were conducted in healthy infants (Bates et al. 1993; Umeta et al. 2000; Osendarp et al.

253 2002; Lind et al. 2003; Wasantwisut et al. 2006; Wessells et al. 2012), six studies were conducted

on infants who were nutritionally at risk (Walravens et al. 1989; Sazawal et al. 1996, 2004; Berger

et al. 2006; Chang et al 2010; Mazariegos et al. 2010; Ba Lo et al. 2011;), and one study was

conducted on infants with poor nutritional status (Makonnen et al. 2003).

Table 3 summaries the internal validity of the included studies, assessed as described in the data

synthesis section. The risk of bias was high in two studies (Bates et al. 1993; Umeta et al. 2000),

five had a moderate risk (Sazawal et al. 1996; 2004; Osendarp et al. 2002; Makonnen et al. 2003;

Berger et al. 2006; Wessells et al. 2012) and six had a low risk of bias (Walravens et al. 1989; Lind

et al 2003; Wasantwisut et al. 2006; Chang et al 2010; Mazariegos et al. 2010; Ba Lo et al. 2011).

262

263 In general, most of the studies found a significant and direct association between Zn intake and

264 serum/plasma Zn status, with β values ranged from 0.031 and 0.233. Only four studies reported no

statistically significant association between Zn intake and serum/plasma Zn status (Walravens et al.

266 1989; Bates et al. 1993; Makonnen et al. 2003; Wessells et al. 2012 (a) Tablets group). In order to

summarize the results we performed a formal meta-analysis (Figure 2).

268

269 Differences between serum/plasma Zn status measured according to the intervention group in each 270 particular study and in the pooled analysis are shown in Figure 2. The pooled β was 0.09 (95%CI 271 (0.05, 0.12). However, a substantial heterogeneity was present in the analyses (1² for status = 98%). 272 In order to investigate which variables may be potential effect modifiers, we performed a meta-273 regression (Table 4). The effect of Zn intake on serum/plasma Zn status changed depending on the 274 duration of the intervention, the dose of supplementation and the nutritional situation (p 275 ANCOVA= 0.054; <0.001 and <0.007) respectively. After stratifying the sample according to the 276 effect modifiers identified in the meta-regression (Table 5) the results by duration of intervention 277 showed no significant effect when the duration was short (1 to 3 weeks) ($\beta = 0.02$; CI 95% -0.03 to 278 (0.07). Nevertheless, a positive effect was shown when Zn intake was provided over medium (4 to 279 20 weeks)($\beta = 0.09$; CI 95% 0.06 to 0.13) and long periods of time (>20 weeks) ($\beta = 0.12$; CI 95% 280 0.07 to 0.16). However these pooled β still revealed high evidence of statistically significant 281 heterogeneity (I²= 91 and 96 %) respectively. When doses of Zn ranged from 4.1 to 8 mg/day, there 282 was no significant effect of Zn intake on the serum/plasma Zn; whereas a positive effect was seen 283 when doses ranged from 8.1 to 12 mg/day ($\beta = 0.12$; CI 95% 0.09 to 0.16). For doses higher than 12 284 mg/day we found no effect. However high evidence of heterogeneity was observed (I^{2} = from 77 to 285 96 %). When studies were categorised by nutritional situation, those studies based on healthy 286 infants and on infants at nutritional risk reported a positive association between Zn intake and 287 serum/plasma Zn status ($\beta = 0.19$; CI 95% 0.04 to 0.13 and $\beta = 0.10$; CI 95% 0.05 to 0.15) 288 respectively. However, no association was found when the nutritional situation was poor ($\beta = 0.05$; 289 CI 95% -0.02 to 0.12). Once again, the pooled β still showed high evidence of heterogeneity (I²= 290 from 95 to 99 %). Due to the high heterogeneity found in all the analyses, we decided to avoid 291 calculating the dose-response relationship between Zn intake and serum/plasma Zn status.

292

293 Discussion

294

Our results indicate that Zn supplementation increases serum/plasma Zn status in infants, as suggested by most of the individual studies. However the results obtained in the meta-analyses were highly heterogeneous. Moreover, after carrying out several subgroup analyses, the pooled β for each sub analysis still showed high evidence of heterogeneity. We argue that conducting a meta-analysis with such data is important in order to highlight the differences between the results of the studies 300 available, rather than to present a unifying synthesis (Delgado-Rodríguez & Sillero Arenas in

301 press).

302

303 The interpretation of these results should be carefully considered for a number of reasons. First, the 304 number of studies that were eligible for inclusion in this meta-analysis was small, which limited the 305 statistical power of the analyses to examine the relation between status responses to Zn 306 supplementation. Thus, the small effect size we found may be explained by the limited amount of 307 available information. Also, it is well acknowledged that when many statistical comparisons are 308 carried out, one or more might reach significance due to chance alone (Bland & Altman 1995). It is 309 also important to consider the scientific quality of included studies. Although meta-analyses are 310 increasingly used to consolidate results from multiple studies of the same topic and to develop 311 evidence-based policies for clinical practice and public health programmes, the reliability of 312 reached conclusions depend on the methodological quality of the original studies, the 313 appropriateness of the study inclusion criteria, and the thoroughness of the review and synthesis of 314 information (Brown et al. 2002). While strict systematic review protocols were followed adhering 315 to EURRECA's quality standards (Matthys et al 2011), an assessment of the risk of bias of included 316 studies revealed that the majority (n=7) had a high to moderate risk of bias.

317

318 Positive effects of Zn supplementation on mean serum Zn concentrations have also been reported in 319 previous meta-analyses conducted in children, pregnant women and adults (Brown et al. 2002; Hess 320 et al. 2007; Hall Moran et al 2012a, Hall Moran et al 2012b; Lowe et al 2012). In these meta-321 analyses, there was a significantly positive effect of Zn supplementation over the mean serum Zn 322 concentrations of the studied population. However, to our knowledge, meta-analytical methods have 323 not yet been used to model serum/plasma Zn status as a function of Zn intake levels in infants. 324 Understanding the relationship between dietary intake and micronutrient status is essential for 325 deriving dietary recommendations.

326

327 Population mean concentration of serum Zn is a useful indicator of the successful delivery and 328 absorption of Zn supplements in infants. Both serum and plasma Zn concentrations are the most 329 widely used biochemical indicators of serum/plasma Zn status but their levels are not necessarily 330 identical. For instance, several biochemical studies designed to compare plasma and serum Zn 331 concentrations observed higher levels of Zn in serum than in plasma (Kasperek et al. 1981; English 332 & Hambidge 1988). These differences may have occurred because serum samples were separated 333 from blood cells after a longer period of time than plasma samples, so more Zn went out from the 334 cells into serum than into plasma. By controlling both, the amount of blood collected and the time

of cell separation, no differences were found in the Zn concentrations of serum and plasma (English
& Hambidge 1988). For the sake of simplicity, this paper referred to "serum/plasma Zn" without
making any distinction between them.

338

339 Some confounders should be considered in evaluating the effect of Zn intake on infant 340 serum/plasma Zn status. Those confounders include low birth weight, breastfeeding, protein energy 341 malnutrition, poverty and social deprivation. The pre-existing serum/plasma Zn status of the study 342 subjects, the content and bioavailability of Zn in the local diets, and the incidence of common 343 infections that can affect individual's serum/plasma Zn status are others important confounders to 344 take into account. Moreover, methodological aspects of these studies, such as variations in the dose, 345 chemical form, method of administration of Zn and duration of supplementation, may have 346 influenced their results (Brown et al. 2002). However, with the exception of Bates et al (1993), all 347 the RCTs included in the meta-analysis assumed no baseline differences in serum/plasma Zn. As all 348 the studies included in our meta-analysis are RCTs we may assume that the randomization has been 349 correct and these factors should not bias the results.

350

351 Age of the study populations considered in this meta-analysis was another important point. We 352 believe that there was no reason to exclude any study that did not adhere exclusively to the group of 353 0 to 12 months of age. For this reason, we took into account all the studies which included this age 354 group in the study, even if they were not analysed according to their age group (Walravens et al. 355 1989; Bates et al. 1993; Makonnen et al. 2003; Sazawal et al. 2004, 1996; Chang et al. 2010; Ba Lo 356 et al. 2011; Wessells et al. 2012) and assumed the consequences of this possible bias. Another 357 confounding factor that might explain the inconsistency in our findings is that serum Zn 358 concentrations vary according to the time of day, proximity of previously consumed meals, and 359 occurrence of recent physical activity or other forms of stress, fluctuating by as much as 20% 360 during a 24-hour period (Hambidge et al. 1989). The diurnal variation in circulating Zn 361 concentration is largely a result of metabolic changes after meal consumption, although some 362 variation may occur as a result of normal circadian variation in metabolism (Guillard et al. 1979; 363 Wallock et al. 1993). Meal consumption results in a decrease in serum/plasma Zn concentrations, 364 which add up following repeated meals (Goode 1991; Wallock et al. 1993), whereas overnight and 365 daytime fasting result in increased circulating Zn concentrations (Wallock et al. 1993). Of the 366 studies included in our meta-analyses, those conducted by Walravens et al. 1989, Umeta et al. 2000, 367 Osendarp et al. 2002, Berger et al. 2006, Wasantwisut et al. 2006, Ba lo et al. 2011 and Wessells et 368 al. 2012 reported the time of the day when the blood samples were collected (during the morning).

369 Due to small numbers it was not possible to conduct a subgroup analysis on the time of the day that

370 the samples were collected.

371

372 Infection and inflammation can decrease serum/plasma Zn values, with the magnitude of change 373 depending on the severity and stage of infection (Brown 1998). In community- based surveys, the 374 reductions in serum/plasma Zn concentration due to infection average $\sim 10\%$ to 12% compared with 375 healthy reference groups (Thurnham et al. 2005). Several other factors, such as low serum albumin, 376 elevated white blood cell counts, use of hormones, can also affect serum/plasma Zn levels and must 377 be considered in the interpretation of laboratory results (IZiNCG 2004). In our meta-analysis, all 378 studies accounted for the presence of disease over the duration of the intervention and whether or 379 not Zn levels were affected by that.

380

381 Infants suffering from protein-energy malnutrition have low concentrations of Zn in serum/plasma, 382 muscle and liver (Hansen & Lehman 1969; Cheek et al. 1970). Because Zn is needed for tissue 383 synthesis during nutritional rehabilitation, the amount required may exceed dietary supply (Castillo-384 Duran et al. 1987; Gibson et al. 1998). Makonnen et al 2003 were the only authors in our meta-385 analysis which included infants with PEM. In this study, improvement in serum/plasma Zn status 386 became evident only after 60 days. In children with PEM it takes over one month for serum levels 387 to increase significantly, so this could explain the limited effect Zn supplementation had on 388 serum/plasma Zn levels at 30 days. Inclusion of a study conducted in malnourished children might 389 have contributed to the lack of significance in the present meta-analysis. Finally, most of the 390 studies were carried out among low-income populations of Asia and Africa and some of them were 391 based on nutritionally at risk subjects so the generalization of the reported estimations to European 392 populations could be compromised.

393

394 In conclusion, a positive significant association was found between Zn intake and serum/plasma Zn 395 status in infants. The magnitude of effect we found was in all cases rather small. Based on this 396 limited group of studies and their heterogeneity, we found insufficient current information to 397 suggest that supplementation of Zn has a positive effect on infants' serum/plasma Zn status or to 398 recommend mean serum/plasma Zn concentration of a given population as a useful predictor of 399 response to Zn supplementation. Further standardized research is urgently needed to reach 400 evidence-based conclusions to clarify the role of Zn supplementation upon infant serum/plasma Zn 401 status, particularly in Europe and other affluent societies.

- 402
- 403

404

4	0	5
	v	~

406 ACKNOWLEDGEMENTS: This research was undertaken as an activity of the European
407 Micronutrient Recommendations Aligned (EURRECA) Network of Excellence (www.eurreca.org),
408 funded by the European Commission Contract Number FP6 036196-2 (FOOD).

- 409 The original concept of the systematic review was undertaken by the EURRECA Network and
- 410 coordinated by partners based at Wageningen University (WU), the Netherlands, and the University
- 411 of East Anglia (UEA), United Kingdom. Susan Fairweather-Tait (UEA), Lisette de Groot (WU),
- 412 Pieter van' t Veer (WU), Kate Ashton (UEA), Amélie Casgrain (UEA), Adriënne Cavelaars (WU),
- 413 Rachel Collings (UEA), Rosalie Dhonukshe-Rutten (WU), Esmée Doets (WU), Linda Harvey
- 414 (UEA) and Lee Hooper (UEA) designed and developed the review protocol and search strategy.
- 415 The authors would also like to thank Lisa Verberne, Catarina Oliveira, Noé Brito García, María del
- 416 Rosario García Luzardo, Noemí Rodríguez Calcines and Yurena García Santos for their assistance
- 417 with the selection of studies and the extraction of data.
- 418 The authors' responsibilities were as follows: MN: analysis of the data and writing the manuscript,
- 419 ALS & MN: review the papers, MWM: contribution to selection of papers and data extraction,
- 420 ASV: support in data-analysis, DFL, PHS, JDA, NL, VMH and LSM provision of significant
- 421 advice. All authors directly participated in the planning, execution or analysis of the study and
- 422 reviewed the manuscript.
- 423
- 424
- 425
- 426 CONFLICT OF INTEREST: Authors declare no conflicts of interest.
- 427
- 428
- 429

430 References

- Ashwell M, Lambert J.P, Alles M.S, Branca F, Bucchini L, Brzozowska A, et al.; EURRECA
 Network (2008) How we will produce the evidence-based eurreca toolkit to support nutrition and
 food policy. Eur J Nutr 47, 2-16.
- 434
- 435 Baer MT, King JC, Tamura T, Margen S, Bradfield RB, Weston WL, et al. (1985) Nitrogen 436 utilization, enzyme activity, glucose intolerance and leukocyte chemotaxis in human experimental
- 437 zinc depletion. Am JClin Nutr **41**, 1220–35.
- 438

- 439 Ba Lo N, Aaron GJ, Hess SY, Guiro AT, Wade S, Brown KH. (2011) Plasma zinc concentration 440 increases within 2 weeks in healthy Senegalese men given liquid supplemental zinc, but not zincfortified wheat bread. J Nutr 141(7):1369-74. 441 442 Bates CJ, Evans PH, Dardenne M, Prentice A, Lunn PG, Northrop-Clewes CA, et al.(1993) A trial 443 of zinc supplementation in young rural Gambian children. Br J Nutr 69, 243–55. 444 445 Berger J, Ninh NX, Khan NC, Lien DK, Trung NQ, Khoi HH (2006) Efficacy of combined iron and 446 zinc supplementation on micronutrient status and growth in Vietnamese infants. Eur J Clin Nutr 447 60(4): 443-54. 448 449 Bland JM, Altman DG (1995) Multiple significance tests: the Bonferroni method. BMJ 21, 310 450 (6973):170. 451 452 Brown KH (1998) Effect of infections on plasma zinc concentration and implications for zinc status 453 assessment in low-income countries. Am J Clin Nutr 68, suppl 2, 425–98. 454 455 Brown KH, Peerson JM, Rivera J, Allen LH (2002) Effect of supplemental zinc on the growth and 456 serum zinc concentrations of prepubertal children: a meta-analysis of randomized controlled trials. 457 Am J Clin Nutr 75, 1062–1071. 458 459 Castillo-Duran C, Heresi G, Fisberg M, Uauy R (1987) Controlled trial of zinc supplementation 460 during recovery from malnutrition: effects on growth and immune function. Am J Clin Nutr 45, 461 602-8. 462 463 Chang S, El Arifeen S, Bari S, Wahed MA, Rahman KM, Rahman MT, et al. (2010) Supplementing iron and zinc: double blind, randomized evaluation of separate or combined delivery. Eur J Clin 464 465 Nutr 64 (2), 153-60. 466 467 Cheek DB, Hill DE, Cordano A, Graham GG (1970) Malnutrition in infancy. Changes in muscle 468 and adipose tissue before and after rehabilitation. Pediatr Res 4, 135-44. 469 470 Chesters JK (1978) Biochemical functions of zinc in animals. World Rev Nutr: Diet 32, 135–64. 471 472 DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin. Trials 7, 177–188. 473 474 Delgado-Rodríguez M, Sillero Arenas M. Revisión sistemática y metaanálisis. En Martinez 475 Gonzalez MA, Alonso A, Guillén Grima F, Sanchez-Villegas A, Tomás Obrador Vera G (eds). 476 Conceptos de salud Pública y estrategias preventivas. Manual para ciencias de la Salud. Elsevier 477 España S.L. 2012 (en prensa). p 55 – 61. 478 479 English JL, Hambidge KM (1988) Plasma and serum zinc concentrations: effect of time between 480 collection and separation. Clin Chim Acta 175, 211–5. 481 482 Gibson RS, Yeudall F, Drost N, Mtitimuni B, Cullinan T(1998) Dietary interventions to prevent zinc deficiency. Am J Clin Nutr 68 (Suppl): 484S-7S. 483
- 484

485 486 487 488	Goode HF, Robertson DA, Kelleher J, Walker BE (1991) Effect of fasting, self-selected and isocaloric glucose and fat meals and intravenous feeding on plasma zinc concentrations. Ann Clin Biochem 28 (5), 442–5.
489 490 491	Greenland S (1998) Meta-analysis. In Modern Epidemiology. eds. K.J. Rothman, & S.S. Greenland pp. 643–673. Philadelphia: Lippincott Raven.
492 493 494	Guillard O, Piriou A, Gombert J, Reiss D (1979) Diurnal variations of zinc, copper and magnesium in the serum of normal fasting adults. Biomedicine 31 , 193–4.
495 496 497 498 499	Hall Moran V, Skinner A, Warthon Medina M, Patel S, Dykes F, Souverein OW, Dullemeijer C, Lowe NM (2012) The relationship between zinc intake and serum/plasma zinc concentration in pregnant and lactating women: a systematic review with dose-response meta-analyses. <i>Journal of Trace Elements in Medicine and Biology</i> 26, 74–79.
500 501 502 503 504 505	Hall Moran V, Skinner A, Warthon Medina M, Patel S, Dykes F, Souverein OW, Dullemeijer C, Pérez-Rodrigo C, Serra-Majem L, Nissensohn M, Lowe NM (2012) The Relationship between Zinc Intake and Serum/Plasma Zinc Concentration in Children: A Systematic Review and Dose-Response Meta-Analysis. <i>Nutrients</i> 4(8), 841-858.
506 507 508	Hambidge KM, Goodall MJ, Stall C, Pritts J (1989) Post-prandial and daily changes in plasma zinc. J Trace Elem Electrolytes Health Dis 3 , 55–7.
509 510	Hambidge M, Krebs N (1995) Assessment of zinc status in man. Indian J Pediatr 62, 157–68.
511 512 513	Hansen DJL, Lehman BH (1969) Serum Zn and copper concentrations in children with protein calorie malnutrition. S Afr Med J 43 , 1248–51.
514 515	Hedges LV (1982) Estimation of effect size from a series of independent experiments. Psychol. Bull 92 , 490–499.
516 517 518	Hermoso M, Tabacchi G, Iglesia-Altaba I, Bel-Serrat S, Moreno-Aznar LA, García-Santos Y, et al. (2010) The nutritional requirements of infants. Towards EU alignment of reference values: the EURRECA network. Maternal & Child Nutrition 6 , suppl 2, 55-83.
519 520 521	Hess SY, Peerson JM, King JC, Brown KH (2007) Use of serum zinc concentration as an indicator of population zinc status. Food Nutr Bull 28 , S403–S429.
522 523 524 525	Higgins JPT, Green S (editors) (2009) Cochrane Handbook for Systematic Reviews for Interventions Version 5.0.2. The Cochrane Collaboration; http://www.cochrane.org/training/cochrane-handbook
526 527 528	International Zinc Nutrition Consultative Group (IZiNCG) (2004) Assessment of the risk of zinc deficiency in populations and options for its control. Hotz C, Brown KH, ed. Food Nutr Bull 25 , suppl 2, S94–S203.

529

530 531 532	Kasperek K, Kiem J, Iyengar GV, Feinendegen LE (1981) Concentration differences between serum and plasma of the elements cobalt, iron, mercury, rubidium, selenium and zinc determined by neutron activation analysis. Sci Total Environ 17 , 133–43.
533 534 535	King JC (1990) Assessment of zinc status. J Nutr 120, 1474–9.
536 537 538 539	Lind T, Lönnerdal B, Stenlund H, Ismail D, Seswandhana R, Ekström EC, et al. (2003) A community-based randomized controlled trial of iron and zinc supplementation in Indonesian infants: interactions between iron and zinc. Am J Clin Nutr 77, 883–90.
540 541 542	Lowe NM, Fekete K, Decsi T (2009) Methods of assessment of zinc status in humans: A systematic review. Am J Clin Nutr 89 , 2040S-2051S.
543 544 545 546 547 548	Lowe NM, Warthon Medina M, Skinner A, , Patel S, , Souverein OW, Dullemeijer C, Serra-Majem L, Nissensohn M, Hall Moran V (2012) The relationship between zinc intake and serum/plasma zinc concentration in adults. A systematic review and dose-response meta-analysis by the EURRECA Network. <i>B J Nutr</i> 108, 1962–1971
548 549 550 551	MacDonald RS (2000) The role of zinc in growth and cell proliferation. J Nutr 130 Suppl 55. 1500S–8S.
552 553 554 555	Makonnen B, Venter A, Joubert G (2003) A randomized controlled study of the impact of dietary zinc supplementation in the management of children with protein–energy malnutrition in Lesotho I: Mortality and morbidity. J Trop Pediatr 49 , 340–52.
556 557 558 559	Makonnen B, Venter A, Joubert G (2003) A randomized controlled study of the impact of dietary zinc supplementation in the management of children with protein-energy malnutrition in Lesotho. II: Special investigations. J Trop Pediatr 49 , 353-60.
560 561 562	Matthys C, van 't Veer P, de Groot L, Hooper L, Cavelaars AE, Collings R, et al. (2011): Eurreca's approach for estimating micronutrient requirements. International J Vit and Nutr Res 81 , 256-263.
563 564 565 566	Mazariegos M, <u>Hambidge KM</u> , <u>Westcott JE</u> , <u>Solomons NW</u> , <u>Raboy V</u> , <u>Das A</u> , <u>Goco N</u> , <u>Kindem M</u> , <u>Wright LL</u> , <u>Krebs NF</u> (2010) Neither a zinc supplement nor phytate-reduced maize nor their combination enhance growth of 6- to 12-month-old Guatemalan infants. J Nutr 140(5):1041-8.
567 568 569 570	Milne DB, Canfield WK, Mahalko JR, Sandstead HH (1983) Effect of dietary zinc on whole body surface loss of zinc: impact on estimation of zinc retention by balance method. Am J Clin Nutr 38 , 181–86.
571 572 573	Osendarp SJ, Santosham M, Black RE, Wahed MA, van Raaij JM, Fuchs GJ (2002) Effect of zinc supplementation between 1 and 6 mo of life on growth and morbidity of Bangladeshi infants in urban slums. Am J Clin Nutr 76 (6), 1401-8.

574

575 576 577 578	Prasad AS (1991): Discovery of human zinc deficiency and studies in an experimental human model. Am J Clin Nutr 53 , 403–12.
579 580 581 582	Sazawal S, Black RE, Bhan MK, Jalla S, Bhandari N, Sinha A, Majumdar S (1996) Zinc supplementation reduces the incidence of persistent diarrhea and dysentery among low socioeconomic children in India. J Nutr 126 (2), 443-50.
583 584 585 586	Sazawal S, Malik P, Jalla S, Krebs N, Bhan MK, Black RE (2004) Zinc supplementation for four months does not affect plasma copper concentration in infants. Acta Paediatr 93 (5), 599-602.
587 588 589	Takkouche B, Cadarso-Suarez C, Spiegelman D (1999) Evaluation of old and new tests of heterogeneity in epidemiologic meta-analysis. Am. J. Epidemiol 150 , 206–215.
590 591 592	Thurnham DI, Mburu AS, Mwaniki DL, De Wagt A (2005) Micronutrients in childhood and the influence of subclinical inflammation. Proc Nutr Soc 64 , 502–9.
593 594 595	Umeta M, West CE, Haider J, Deurenberg P, Hautvast JG (2000) Zinc supplementation and stunted infants in Ethiopia: a randomized controlled trial. Lancet 355 , 2021–6.
596 597 598	Wallock LM, King JC, Hambidge KM (1993) Meal-induced changes in plasma, erythrocyte, and urinary zinc concentrations in adult women. Am J Clin Nutr 58 , 695–701.
599600601	Walravens PA, Hambidge KM, Koepfer DM (1989) Zinc supplementation in infants with a nutritional pattern of failure to thrive: a double-blind controlled study. Pediatrics 83 , 532–38.
602 603 604 605	Wasantwisut E, Winichagoon P, Chitchumroonchokchai C, Yamborisut U, Boonpraderm A, Pongcharoen T, et al.(2006) Iron and zinc supplementation improved iron and zinc status, but not physical growth, of apparently healthy, breast-fed infants in rural communities of northeast Thailand. J Nutr 136 (9), 2405-11.
606 607 608 609 610	Wessells <u>KR</u> , <u>Ouédraogo ZP</u> , <u>Rouamba N</u> , <u>Hess SY</u> , <u>Ouédraogo JB</u> , <u>Brown KH</u> (2012) Short-term zinc supplementation with dispersible tablets or zinc sulfate solution yields similar positive effects on plasma zinc concentration of young children in Burkina Faso: a randomized controlled trial. J Pediatr 160(1):129-35.
611 612	World Health Organization. Nutrition for health and development. WHO, Geneva, 1999.

Figure 1: Flow diagram for the systematic review.




Figure 2	: Forest Plot of	f RCTs evaluating th	e effect of zinc ir	ntake on serum/plasma zin	c
	status in infa	ints			

				BETA	BETA
Study or Subgroup	BETA	SE	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
Ba Lo 20011	0.05921769	0.003973	5.1%	0.06 [0.05, 0.07]	
Bates, 1993a	-0.00051974	0.0105164	5.0%	-0.00 [-0.02, 0.02]	
Bates, 1993b	0.03166414	0.0057522	5.1%	0.03 [0.02, 0.04]	2. .
Berger 2006	0.17533735	0.0029027	5.1%	0.18 [0.17, 0.18]	
Chang, 2010	0.03736004	0.0153694	4.9%	0.04 [0.01, 0.07]	
Lind, 2003	0.1145842	0.0072846	5.1%	0.11 [0.10, 0.13]	
Makonnen, 2003a	-0.00907326	0.0124158	5.0%	-0.01 [-0.03, 0.02]	
Makonnen, 2003b	0.05789898	0.0153531	4.9%	0.06 [0.03, 0.09]	- •
Makonnen, 2003c	0.11079844	0.0148662	4.9%	0.11 [0.08, 0.14]	
Mazariegos 2010	0.04677569	0.0725893	2.6%	0.05 [-0.10, 0.19]	at a st 19
Osendrap, 2002	0.12128316	0.0138216	4.9%	0.12 [0.09, 0.15]	
Sazawal, 1996 - 2004a	0.16376497	0.0236563	4.6%	0.16 [0.12, 0.21]	
Sazawal, 1996 - 2004b	0.08166184	0.0257183	4.6%	0.08 [0.03, 0.13]	
Sazawal, 1996 - 2004c	0.14984787	0.0243767	4.6%	0.15 [0.10, 0.20]	
Sazawal, 1996 - 2004d	0.1134876	0.018524	4.8%	0.11 [0.08, 0.15]	
Sazawal, 1996 - 2004e	0.13542532	0.0210504	4.7%	0.14 [0.09, 0.18]	
Umeta, 2000a	0.17332506	0.0284875	4.5%	0.17 [0.12, 0.23]	- ÷
Umeta, 2000b	0.09082382	0.030659	4.4%	0.09 [0.03, 0.15]	
Walravens, 1989	-0.07779454	0.064586	2.9%	-0.08 [-0.20, 0.05]	24 <u>8</u> 0
Wasantwisut, 2006	0.23362817	0.0208732	4.7%	0.23 [0.19, 0.27]	-
Wessells 2012 a (Tablets)	-0.01835255	0.0445956	3.7%	-0.02 [-0.11, 0.07]	
Wessells 2012 b (liquid)	0.00400245	0.0451927	3.7%	0.00 [-0.08, 0.09]	
Fotal (95% CI)			100.0%	0.09 [0.05, 0.12]	-

Table 1: Search strategy: MEDLINE February 2010

(MEDLINE home page. Available online: http://www.ncbi.nlm.nih.gov/pubmed/)

No.	Search term	Results
1	randomized controlled trial.pt.	280,821
2	controlled clinical trial.pt.	79,998
3	randomised.ab.	196,604
4	placebo.ab.	117,891
5	clinical trials as topic.sh.	146,242
6	randomly.ab.	145,491
7	trial.ab.	203,467
3	randomised.ab.	38,423
)	6 or 3 or 7 or 2 or 8 or 1 or 4 or 5	734,511
10	(animals not (human and animals)).sh.	4,482,479
1	9 not 10	642,665
12	(cohort* or "case control*" or cross-sectional* or "cross sectional" or case-control* or prospective or "systematic review*").mp.	768,885
13	exp meta-analysis/ or expmulticenter study/ or follow-up studies/ or prospective studies/ or intervention studies/ or epidemiologic studies/ or case-control studies/ or exp cohort studies/ or longitudinal studies/ or cross- sectional studies/	1,013,635
4	13 or 12	1,203,767
5	14 not 10	1,154,385
16	11 or 15	1,599,094
17	((zinc or zn or zinc sulphate or zinc gluconate or zinc acetate or methionine or zinc isotope*) adj3 (intake* or diet* or supplement* or deplet* or status or serum or plasma or leukocyte or concentration* or expos* or fortif* or urine or hair)).ti,ab.	16,681
8	Nutritional Support/ or Dietary Supplements/ or nutritional requirements/ or Breast feeding/ or exp infant food/ or bottle feeding/ or infant formula/	63,098
19	exp Nutritional Status/ or exp Deficiency Diseases/ or supplementation/ or diet supplementation/ or dietary intake/ or exp diet restriction/ or exp mineral intake/ or Diet/ or Food, Fortified/ or nutrition assessment/ or Nutritive Value/	176,014
20	(intake* or diet* or supplement* or deplet* or status or serum or plasma or leukocyte or concentration* or expos* or fortif* or urine or hair).ti,ab.	3,166,092
21	18 or 19 or 20	3,263,114
22	zinc/	41,027
23	22 and 21	20,745
24	23 or 17	26,943
25	24 and 16	2410

Table 2: Characteristics of the 13 (22 estimations) Status studies included in the meta-analysis

Author	Study year	Country	Sample Age range or Mean (SD)	Number of Infants (n)		Doses of Zinc/ day			Nutritional situation	Risk of bias ²
				Zn ¹	C'					
Ba Lo	2011	Senegal	9 to 17 months	33	32	6 mg	15 days	Status (plasma)	Nutritionally at risk	Low risk
Bates (a)	1993	Gambia	5.7 to 27 months	30	28	20 mg	2 weeks	Status (plasma)	Healthy	High risk
(b)				46	44		8 weeks			
Berger	2006	Vietnam	4 to 7 month	161	155	10 mg	24 weeks	Status (serum)	Nutritionally at risk	Moderate risk
Chang	2010	Bangladesh	6 to 18 months	85	89	2,5 mg	24 weeks	Status (serum)	Nutritionally at risk	Low risk
Lind	2003	Indonesia	6.1 (0.5) months	134	143	10 mg	24 weeks	Status (serum)	Healthy	Low risk
(a)	2003	Lesotho	6 to 60 months	142	121	10 mg	4 weeks	Status (serum)	Poor nutritional status	Moderate risk
Makonnen (b)				141	119		8 weeks			
(c)				138	116		12 weeks			
Mazariegos	2010	Guatemala	6 to 12 months	24	29	5 mg	24 weeks	Status (plasma)	Nutritionally at risk	Low risk
Osendarp	2002	Bangladesh	3 to 5 weeks	138	133	5 mg	20 weeks	Status (serum)	Healthy	Moderate risk
Sazawal (a)	1996-	India	6 to 35 months	223	224	10 mg	16 weeks	Status (plasma)	Nutritionally at risk	Moderate risk
(b)	2004 ³		6 to 11 months	78	78					
(c)			> 11 months	69	73					
(d)			Females	115	106					
(e)			Males	108	118					

(a)	2000	Ethiopia	Zinc stunted9.5 (2.0) moPlacebo stunted9.7 (2.0) mo	25	25	8,57 mg	24 weeks	Status (serum)	Healthy	High risk
Umeta										
			Zinc non stunted 9.3 (2.1) mo							
(b)			Placebo non stunted 9.2 (2.0) mo	25	25					
Walravens	1989	USA	8 to 27 months	16	25	5,7 mg	24 weeks	Status (plasma)	Nutritionally at risk	Low risk
Wasantwisut	2006	Thailand	4 to 6 months	58	66	10 mg	24 weeks	Status (serum)	Healthy	Low risk
Wessells	2012	Burkina	6 to 23 month		150	5 mg	3 weeks	Status (plasma)	Healthy	Moderate risk
		Faso								
(a)Tablets				149						
(b)Liquid				146						

(a - e): Estimations

¹Zn: Zinc group / ¹C: Control group

² Low risk of bias meant that the study was randomized, the randomization method was at least partially described, reasons for and numbers of dropouts were stated (or there were no dropouts), and the method used to assess compliance and some assessment of compliance were reported. All others studies were considered as moderate when they meet any of the above criteria or high risk of bias when they meet any of the criteria. (Higgins 2009, Cochrane Handbook)

³Companion paper

Table 3: Assessment of internal validity in RCTs of serum/plasma Zn status.

Author, Year	Method of sequence	Adequate allocation	Blinding adequate	Number at start, dropouts & dropouts reasons	Funder adequate	Others potential funding bias	Overall risk of bias
	generation			Outcome data complete			
Ba Lo 2011	Yes	Yes	Yes	Yes	Yes	Yes	Low risk
Bates 1993 Berger 2006	Yes Unclear	No Unclear	Unclear Yes	Yes	No Yes	No Yes	High risk Moderate risk
Chang 2010	Yes	Yes	Yes	Yes	Yes	Yes	Low risk
Lind 2003	Yes	Yes	Yes	Yes	Yes	Yes	Low risk
Makonnen 2003	Yes	Unclear	Yes	Yes	Unclear	Yes	Moderate risk
Mazariegos 2010	Yes	Yes	Yes	Unclear	Yes	Yes	Low risk
Osendarp 2002	Unclear	Unclear	Yes	Yes	Yes	Yes	Moderate risk
Sazawal 1996-2004	Unclear	Unclear	Yes	Unclear	Yes	Yes	Moderate risk
Umeta 2000	Unclear	Unclear	Yes	Unclear	Unclear	Yes	High risk
Walravens 1989	Yes	Unclear	Yes	Yes	Yes	Yes	Low risk
Wasantwisut 2006	Yes	Yes	Yes	Yes	Yes	Yes	Low risk
Wessells 2012	Yes	Yes	No	Yes	Yes	Yes	Moderate risk

Table 4: Meta-regression. Multivariate adjusted mean beta for Status (95% confidence interval) by different ch	aracteristics of the
studies included in the meta-analysis	

	n	Mean Beta's	CI (95%)	P Ancova*
Status				
By duration of the intervention				
1 to 3 weeks	4	0.0221	-0.0752 to 0.1194	
4 to 20 weeks	10	0.0543	0.0142 to 0.0943	
> 20 weeks	8	0.1331	0.0805 to 0.1858	
				0.054
By Dose				
1 to 4 mg	1	-0.1025	-0.2081 to 0.0031	
4,1 to 8 mg	6	0.1893	0.1021 to 0.2764	
8,1 to 12 mg	13	0.1070	0.0650 to 0.1491	
> 12 mg	2	0.0855	0.0215 to 0.1495	
				< 0.001
By Nutritional situation				
Healthy	9	0.0456	0.0048 to 0.0863	
Nutritionally at risk	10	0.1184	0.0686 to 0.1681	
Poor nutritional situation	3	0.0456	0.0048 to 0.0863	
				< 0.007
By Risk of Bias				
Low	6	0.0978	0.0351 to 0.1606	
Moderate	12	0.0558	0.0140 to 0.0976	
High	4	0.0558	0.0140 to 0.0976	
				0.255

* Adjusted for the rest of variables in the table

Table 5: Pooled beta (95% confidence intervals) in Status according to the intervention group. Subgroup analyses.

	Pooled estimates (β)	Chi ² (df, P)	I^2
Status			
All Studies (n=22)	0.09 (0.05 to 0.12)	1166.30 (21, < 0.00001)	98%
By duration of the intervention			
1 to 3 weeks (n=4)	0.02 (-0.03 to 0.07)	31.78 (3, < 0.00001)	91%
4 to 20 weeks (n=10)	0.09 (0.06 to 0.13)	141.21 (9, < 0.00001)	94%
> 20 weeks (n=8)	0.12 (0.07 to 0.16)	162.64 (7, < 0.00001)	96%
By dose	2		
1 to 4 mg (n=1)	0.04 (0.01 to 0.07)		
4,1 to 8 mg (n=6)	0.04 (-0.01 to 0.09)	22.08 (5, 0.0005)	77%
8,1 to 12 mg (n=13)	0.12 (0.09 to 0.16)	341.12 (12, <0.00001)	96%
> 12 mg (n=2)	0.02 (-0.01 to 0.05)	7.21 (1, 0.007)	86%
By Nutritional Situation			
Healthy (n=9)	0.09 (0.04 to 0.13)	220.90 (8, < 0.00001)	96%
Nutritionally at risk (n=10)	0.10 (0.05 to 0.15)	615.54 (9, < 0.00001)	99%
Poor nutritional status (n=3)	0.05 (-0.02 to 0.12)	39.26 (2, < 0.00001)	95%

*I² Index measures the extent of the heterogeneity